Lilly acquires compounds to begin TB initiative
This article was originally published in Scrip
Executive Summary
Lillyhas signed co-development agreements with Summitand the Japanese organisation Microbial Chemistry Research Foundation (MCRF) to develop tuberculosis drug candidates in its TB Drug Discovery Initiative, a not-for-profit public-private partnership.